Patient management problem-preferred responses.

Learning Objectives Upon completion of this activity, the participant will be able to: & Discuss the optimal medical and neurologic management of patients with high-grade gliomas & Recognize the most frequent adverse events related to treatments in patients with high-grade gliomas & Choose the best treatment for patients with high-grade gliomas & Recognize the pitfalls and advantages of neuroimaging studies in high-grade gliomas Address correspondence to Dr Jordi Bruna, Feixa Llarga Street s/n 08907, Hospital Universitari de Bellvitge. Hospitalet del Llobregat, Barcelona, Spain, [email protected]. Relationship Disclosure: Dr Bruna reports no disclosure. Dr Wen has served as a consultant for AbbVie, Inc; Celldex Therapeutics; Cubist Pharmaceuticals, Inc; Foundation Medicine, Inc; Genentech, Inc; Midatech Ltd, Momenta Pharmaceuticals; Novartis AG; Sigma-Tau Pharmaceuticals, Inc; and Vascular Biogenics Ltd; and serves as section editor, Neuro-oncology, for UpToDate, Inc, and as editor-in-chief for Neuro-oncology. Dr Wen has received personal compensation for speaking engagements from Merck & Co, Inc. Unlabeled Use of Products/Investigational Use Disclosure: Drs Bruna and Wen report no disclosure. * 2015, American Academy of Neurology.